Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Sells 209,818 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. lessened its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 33.1% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 423,272 shares of the company’s stock after selling 209,818 shares during the quarter. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. owned approximately 0.53% of Viridian Therapeutics worth $8,114,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in VRDN. Voya Investment Management LLC increased its stake in shares of Viridian Therapeutics by 5.1% in the 4th quarter. Voya Investment Management LLC now owns 21,397 shares of the company’s stock valued at $410,000 after acquiring an additional 1,038 shares in the last quarter. Tudor Investment Corp ET AL lifted its stake in shares of Viridian Therapeutics by 3.0% in the fourth quarter. Tudor Investment Corp ET AL now owns 38,367 shares of the company’s stock valued at $735,000 after buying an additional 1,106 shares in the last quarter. R Squared Ltd acquired a new position in shares of Viridian Therapeutics during the fourth quarter valued at about $26,000. Summit Investment Advisors Inc. increased its holdings in Viridian Therapeutics by 24.7% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company’s stock worth $147,000 after purchasing an additional 1,516 shares in the last quarter. Finally, AlphaQuest LLC raised its position in Viridian Therapeutics by 119.0% in the 4th quarter. AlphaQuest LLC now owns 2,795 shares of the company’s stock valued at $54,000 after buying an additional 1,519 shares during the last quarter.

Wall Street Analyst Weigh In

VRDN has been the subject of several recent analyst reports. JMP Securities reduced their target price on Viridian Therapeutics from $42.00 to $38.00 and set a “market outperform” rating for the company in a report on Wednesday, May 7th. The Goldman Sachs Group lowered their price objective on Viridian Therapeutics from $31.00 to $27.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. Royal Bank of Canada lowered their target price on shares of Viridian Therapeutics from $46.00 to $45.00 and set an “outperform” rating on the stock in a report on Wednesday, May 7th. Needham & Company LLC reduced their price target on Viridian Therapeutics from $38.00 to $36.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. Finally, HC Wainwright reiterated a “buy” rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a research report on Wednesday, April 23rd. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $36.70.

Viridian Therapeutics Stock Performance

NASDAQ VRDN opened at $12.82 on Tuesday. Viridian Therapeutics, Inc. has a 52-week low of $9.90 and a 52-week high of $27.20. The company has a fifty day moving average of $13.33 and a 200-day moving average of $17.04. The company has a market capitalization of $1.05 billion, a P/E ratio of -2.97 and a beta of 0.57. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.95) by $0.08. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The firm had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.16 million. The business’s revenue for the quarter was up .0% on a year-over-year basis. As a group, equities research analysts predict that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.